Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning

Psychopharmacology

Volumn 169, Issue 3-4, 2003, Pages 321-331

  McDonald, L M ^a,b   Moran, P M ^a,c   Vythelingum, G N ^a   Joseph, M H ^a,c   Stephenson, J D ^a   Gray, J A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

5 HT2A receptor antagonists; Antipsychotic; Latent inhibition; Schizophrenia

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 2 [[2 (DIMETHYLAMINO)ETHYL]THIO] 3 PHENYLQUINOLINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 HYDROXYTRYPTOPHAN; AMPHETAMINE; EPLIVANSERIN; NEUROLEPTIC AGENT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPOSURE; FOREFOOT; HEAD TWITCH; IN VIVO STUDY; LATENT INHIBITION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WET DOG SHAKES;

5-HYDROXYTRYPTOPHAN; 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; AGING; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ASSOCIATION LEARNING; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, CLASSICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUOROBENZENES; INHIBITION (PSYCHOLOGY); MALE; PHENCYCLIDINE; PHENOLS; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGONISTS; STEREOTYPED BEHAVIOR;

EID: 0141958828     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1173-4     Document Type: Article

References (69)

1. Alves CRR, Silva MTA (2001) Facilitation of latent inhibition by the atypical antipsychotic risperidone. Pharmacol Biochem Behav 68:503-506
2. 2 agonist DOI. Eur J Pharmacol 161:45-51
3. Arranz MJ, Collier DA, Sodhi M, Ball D, Roberts G, Price J, Sham P Kerwin R (1995) Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346:281-282
4. 2A receptor gene and response to clozapine. Mol Psychiatry 3:61-66
5. Badri F, Masellis M, Petronis A, Macciardi FM, Van Tol HHM, Cola P, Meltzer HY, Lieberman J, Potkin S, Kennedy JL (1996) Dopamine and serotonin system genes may predict clinical response to clozapine. Am J Hum Genet 59[Suppl]:A247
6. Blackburn TP, Thorber CW, Pearce RJ, Cox B (1988) In vitro studies with ICI 169,369, a chemically novel 5-HT antagonist. Eur J Pharmacol 150:247-256
7. 1C receptor antagonist. Eur J Pharmacol 180:229-237
8. Cassaday HJ, Hodges H, Gray JA (1993a) The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat. J Psychopharmacol 7:63-71
9. Cassaday HJ, Mitchell SN, Williams JH, Gray JA (1993b) 5,7-Dihydroxytryptamine lesions in the fornix-fimbria attenuate latent inhibition. Behav Neural Biol 59:194-207
10. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40
11. Dekeyne A, Lob I, Hautefaye P, Millan MJ (2001) Discriminative stimulus properties of the selective serotonin (5-HT)2A antagonist, MDL 100,907, in rats. Behav Pharmacol 12[Suppl 1]:S28
12. 2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J Neurochem 73:1033-1042
13. Dickinson SL, Curzon G (1983) Roles of dopamine and 5-hydroxytryptamine in stereotyped and non-stereotyped behaviour. Neuropharmacology 22:805-812
14. Dunn LA, Atwater GE, Kilts CD (1993) Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioural model of clinical drug action. Psychopharmacology 112:315-323
15. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544
16. Feldon J, Weiner I (1991) The latent inhibition model of schizophrenic attentional disorder: haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29:635-646
17. 1A receptor antagonist. Behav Brain Res 73:337-353
18. Gewirtz GW, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison R (1994) BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10:37-40
19. Goldstein JM, Litwin LC, Sutton EB, Malick JB (1989) Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 249:673-680
20. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14:1-84
21. Gray JA, Joseph MH, Hemsley DR, Young AMJ, Warburton EC, Boulenguez P, Grigoryan G, Peters SL, Rawlins JNP, Taib C-T, Yee BK, Cassaday H, Weiner I, Gal G, Gusak O, Joel D, Shadach E, Shalev U, Tarrasch R, Feldon J (1995) The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res 71:19-31
22. Gray JA, Moran PM, Grigoryan G, Peters SL, Young AMJ, Joseph MH (1997) Latent inhibition: the nucleus accumbens connection revisited. Behav Brain Res 88 27-34
23. Greenshaw AJ, Silverstone PH (1997) The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Drugs 53:20-39
24. Howell DC (1992) Statistical methods for psychology, 3rd edn. Duxbury Press, Belmont
25. Joseph MH, Peters SL, Moran PM, Grigorian GA, Young AMJ, Gray JA (2000) Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning. Neuroscience 30:921-930
26. Kapur S, Remington G (1996) Serontonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476
27. 2C/2B receptor function. Neuropharmacology 33:1581-1588
28. 2C receptor antagonist. Neuropharmacology 36:609-620
29. Killcross AS, Dickinson A, Robbins TW (1994) Effects of the neuroleptic α-flupenthixol on latent inhibition in aversively-and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology 115:196-205
30. 2 receptors and wet-dog shakes in rats. Eur J Pharmacol 118:273-281
31. Kufferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brucke T, Kasper S (1997) IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 133:323-328
32. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44:1099-1117
33. Lucki I, Ward HR, Frazer A (1989) Effect of 1-(m-chlorophenyl) piperazine and 1-(m-trifluoromethylphenyl) piperazine on locomotor activity. J Pharmacol Exp Ther 249:155-165
34. 3H]RP 62203 binding in the rat brain. Eur J Pharmacol 233:37-45
35. Meltzer HY (1999) The role of serotonin in antipyschotic drug action. Neuropsychopharmacology 21:1068-1158
36. 2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419-4432
37. 1A agonist properties. IV. A drug discrimination comparison with clozapine. J Pharmacol Exp Ther 289:427-436
38. Moran PM, Fischer TR, Hitchcock JM, Moser PC (1996) Effects of clozapine on latent inhibition in the rat. Behav Pharmacol 7:42-48
39. 2 antagonist MDL 100,907 on latent inhibition in the rat. Behav Pharmacol 5:120-121
40. 2A antagonist. Behav Brain Res 73:163-167
41. Moser PC, Lister S, Hitchcock JM, Moran PM (2000) The pharmacology of latent inhibition in the rat: a review of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33:247-282
42. Murphy CA, Pezze M-A, Feldon J, Heidbreder C (2000) Differential involvement of dopamine in the shell and core of the nucleus accumbens in the expression of latent inhibition to an aversively conditioned stimulus. Neuroscience 97:469-477
43. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110:365-367
44. Nordström A-L, Farde L, Wiesel F-A, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993b) Central D2-dopamine receptor occupance in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
45. Peters SL, Joseph MH (1993) Haloperidol potentiation of latent inhibition in rats: evidence for a critical role at conditioning rather than pre-exposure. Behav Pharmacol 4:183-186
46. PRNewswire (1999) Hoechst Marion Roussel announces management decisions on priority pipeline products. Frankfurt, Germany, July 22
47. 2 receptor antagonist. J Pharmacol Exp Ther 262:759-768
48. 2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 receptor blockade. J Pharmacol Exp Ther 253:1162-1170
49. Sanofi-Synthélabo (2001) Information Meeting, 3-4 September 2001. http://www.sanofi-synthelabo.com/us/ANALYSTES0901AN. pdf, pp 44-47
50. 1A agonists. J Pharmacol Exp Ther 273:101-112
51. Schroeder U, Schroeder H, Darius J, Grecksch G, Sabel BA (1998) Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Behav Brain Res 97:59-68
52. Shadach E, Weiner I, Feldon J (1999) Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: implications for the mechanism of action of antipsychotic drugs. Int J Neuropsychopharmacol 2:283-291
53. Shadach E, Gaisler I, Schiller D, Weiner I (2000) The latent inhibition model dissociates between clozapine, haloperidol and ritanserin. Neuropsychopharmacology 23:151-161
54. Solomon PR, Kiney CA, Scott DR (1978) Disruption of latent inhibition following systemic administration of parachlorophenylalanine (PCPA). Physiol Behav 20:265-271
55. Solomon PR, Nichols GL, Kiernan JM III, Kramer RS, Kaplan LJ (1980) Differential effects of lesions in medial and dorsal raphe of the rat: latent inhibition and septohippocampal serotonin levels. J Comp Physiol Psychol 94:145-154
56. Solomon PR, Crider A, Winkelman JW, Turi A, Kramer RM, Kaplan LJ (1981) Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol Psychiatry 16:519-537
57. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioural, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691
58. 1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino) tetralin in the rat. Eur J Pharmacol 106:271-282
59. Tricklebank MD, Forler C, Middlemiss DN, Fozard JR (1985b) Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-n,n-dimethyltryptamine in the rat. Eur J Pharmacol 117:15-24
60. Trimble KM, Bell R, King DJ (1997) Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. Pharmacol Biochem Behav 56:809-816
61. Wadenberg M-LG, Hicks PB, Richter JT, Young KA (1998) Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin 2A receptor antagonist MDL 100,907. Biol Psychiatry 44:508-515
62. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994) Antagonism of amphetamine-induced of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114:657-664
63. Warburton EC, Mitchell SN, Joseph MH (1996) Calcium dependence of sensitised dopamine release in rat nucleus accumbens following amphetamine challenge: implications for the disruption of latent inhibition. Behav Pharmacol 7:119-129
64. Weiner I, Feldon J (1987) Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology 91:248-253
65. Weiner I, Feldon J (1997) The switching model of latent inhibition: an update of neural substrates. Behav Brain Res 88:11-25
66. Weiner I, Lubow RE, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30:871-878
67. Weiner I, Kidron R, Tarrasch R, Arnt J, Feldon J (1994) The effects of the new antipsychotic, sertindole, on latent inhibition in rats. Behav Pharmacol 5:119-124
68. Weiner I, Traub A, Rawlins JNP, Smith AD, Feldon J (1995) The sigma ligand BMY-14802 as a potential antipsychotic: evidence from the latent inhibition model in rats. Behav Pharmacol 6:46-54
69. Young AMJ, Joseph MH, Gray JA (1993) Latent inhibition of conditioned dopamine release in rat nucleus accumbens. Neuroscience 54:5-9